Dow Jones
36 245,50 +294,60 (+0,82 %) Nasdaq
14 305,03 +78,83 (+0,55 %) Nikkei 225
33 196,79 -234,72 (-0,70 %) EUR/USD
1,0878 -0,0007 (-0,07 %) HANG SENG
16 729,01 -101,29 (-0,60 %) Bitcoin EUR
37 433,61 +1 181,06 (+3,26 %)
MRK Jan 2025 125.000 put
| Clôture précédente | 22,50 |
| Ouverture | 22,50 |
| Offre | 0,00 |
| Vente | 0,00 |
| Prix d’exercice | 125,00 |
| Date d’expiration | 2025-01-17 |
| Var. jour | 22,50 - 22,50 |
| Gamme de contrats | S.O. |
| Volume | |
| Position de place | 233 |
ACCESSWIREMRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA, Merck's anti-PD-1 therapy, has been granted Priority Medicines (PRIME) scheme designation by the European Medicines Agency (EMA) for the adjuvant
- ACCESSWIRE
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA®, Merck's anti-PD-1 therapy, demonstrated a statistically significant and clinically meaningful
